Zeneca "superstatin"
Executive Summary
First regulatory submission for ZD4522, an HMG-CoA reductase inhibitor with a "superstatin" profile, is expected in three years, Zeneca says. ZD4522 "has the potential at well tolerated doses of lowering" LDL-cholesterol and triglycerides "to a much greater extent than the first generation of statins," according to the company. Zeneca licensed ZD4522 (formerly S-4522) from Japan-based Shionogi and has taken on worldwide development, commercialization and marketing for the agent...
You may also be interested in...
AstraZeneca Emphasizes Size As Key To Growth In Rx Market
AstraZeneca is guiding investors in the pharmaceutical industry to consider size - both in terms of corporate resources and individual products - as the key to growth.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011